Seres Competitors

Stocks . Germany . 
Stock . Seres Therapeutics
1S9 Stock  EUR 0.84  0.01  1.20%   
Seres Therapeutics competes with Perseus Mining, SOUTHWEST AIRLINES, DISTRICT METALS, American Airlines, and AEGEAN AIRLINES; as well as few others. The company classifies itself under Healthcare sector and is part of Biotechnology industry. Analyzing Seres Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Seres Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Seres Therapeutics Correlation with its peers.
For more detail on how to invest in Seres Stock please use our How to Invest in Seres Therapeutics guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Seres Therapeutics competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.040.838.76
Details
Intrinsic
Valuation
LowRealHigh
0.030.678.60
Details

Seres Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Seres Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Seres and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Seres Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
SWN
+ 0.95
SWN
SWN
+ 0.93
A1G
A1G
+ 0.91
SWN
DFPP
+ 0.65
P4Q
DFPP
+ 0.3
SWN
A1G
+ 0.29
DFPP
  
High negative correlations   
32A
- 0.78
SWN
SWN
- 0.77
32A
32A
- 0.73
A1G
32A
- 0.13
DFPP
32A
- 0.05
P4Q
SWN
- 0.0
CTE

Risk-Adjusted Indicators

There is a big difference between Seres Stock performing well and Seres Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Seres Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Seres Therapeutics Competitive Analysis

The better you understand Seres Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Seres Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Seres Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
1S9 P4Q SWN DFPP CTE A1G 32A SWN
 1.20 
 0.84 
Seres
 1.18 
 1.67 
Perseus
 0.47 
 31.80 
SOUTHWEST
 4.35 
 0.24 
DISTRICT
 0.00 
 0.07 
CHINA
 2.75 
 16.79 
American
 1.39 
 9.91 
AEGEAN
 0.63 
 31.62 
Southwest
Market Volatility
(90 Days Market Risk)
Out of control
Risky
Very steady
Out of control
Very steady
Not too volatile
Not too volatile
Very steady
Market Performance
(90 Days Performance)
Weak
Modest
Good
OK
Very Weak
Solid
Very Weak
Good
Odds of Financial Distress
(Probability Of Bankruptcy)
Below Average
Low
Low
Average
Quite High
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Under Valued
Fairly Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Hold
Strong Sell
Strong Sell
Strong Sell
Strong Buy
Hold
Strong Hold
Current Ratio
5.79 X
1.91 X
N/A
15.98 X
N/A
1.05 X
N/A
1.54 X
Net Asset
354.86 M
1.99 B
35.37 B
N/A
645.84 M
64.72 B
1.54 B
35.37 B
Profit Margin
N/A
0.24 %
N/A
N/A
(0.85) %
0 %
N/A
0.02 %
EBITDA
(56.72 M)
504.39 M
2.38 B
N/A
34.38 M
4.45 B
N/A
2.38 B
Operating Margin
(17.02) %
0.29 %
N/A
N/A
(0.65) %
0.05 %
N/A
0.05 %
Current Valuation
582.79 M
1.75 B
18.11 B
N/A
17.9 M
39.97 B
784.05 M
18.11 B
Price To Book
12.02 X
2.05 X
2.04 X
N/A
0.32 X
N/A
1.77 X
2.03 X
Five Year Return
N/A
N/A
N/A
N/A
N/A
1.27 %
N/A
1.04 %
Beta
2.68
0.89
N/A
0.89
0.14
1.54
N/A
1.14
Number Of Employees
333
25
N/A
N/A
351
129.7 K
18
66.66 K
Shares Outstanding
124.59 M
1.37 B
N/A
86.98 M
2.64 B
651.43 M
N/A
594.29 M
Cash Flow From Operations
6.69 M
522.91 M
3.79 B
(1.07 M)
21.7 M
2.17 B
N/A
3.79 B
Annual Yield
N/A
0.01 %
0.02 %
N/A
N/A
0.03 %
0.14 %
0.02 %
Total Debt
24.64 M
72.54 M
8.05 B
N/A
N/A
32.39 B
343.7 M
8.05 B
Return On Equity
-1.9
0.24
N/A
-0.21
-0.19
N/A
N/A
0.0511
Z Score
14.4
15.0
1.2
N/A
N/A
N/A
0.6
1.2
Return On Asset
-0.4
0.13
N/A
-0.13
-0.0793
0.0212
N/A
0.0191
Book Value Per Share
0.54 X
1.20 X
N/A
0.09 X
0.20 X
(8.91) X
N/A
17.99 X
Total Asset
354.86 M
1.99 B
35.37 B
N/A
645.84 M
64.72 B
1.54 B
35.37 B
Debt To Equity
0.23 %
9.30 %
N/A
N/A
N/A
N/A
N/A
1.37 %
Target Price
20.57
N/A
N/A
N/A
N/A
N/A
N/A
65.4
Last Dividend Paid
N/A
0.027
N/A
N/A
N/A
N/A
0.6
0.18
Shares Owned By Institutions
85.90 %
58.01 %
N/A
1.39 %
0.03 %
55.50 %
N/A
76.80 %
Market Capitalization
608.32 M
1.83 B
22 B
7.8 M
31.45 M
9.78 B
441.82 M
18.72 B
Price To Earning
N/A
(3.55) X
N/A
N/A
N/A
2.45 X
N/A
104.75 X
Price To Earnings To Growth
N/A
N/A
0.42 X
N/A
N/A
0.66 X
N/A
0.42 X
Price To Sales
50.23 X
1.65 X
1.05 X
N/A
0.85 X
0.17 X
0.47 X
0.92 X
Net Income
(65.58 M)
233.59 M
539 M
(2.83 M)
11.34 M
127 M
N/A
539 M
Earnings Per Share
(2.18) X
0.14 X
N/A
(0.02) X
(0.01) X
0.18 X
N/A
0.82 X
Shares Owned By Insiders
6.66 %
0.54 %
N/A
4.43 %
51.51 %
1.22 %
N/A
0.37 %
Revenue
144.93 M
1.13 B
23.81 B
N/A
208.37 M
48.97 B
N/A
23.81 B
Cash And Equivalents
253.62 M
23.04 M
N/A
5.04 M
N/A
17.95 B
N/A
16.87 B
Cash Per Share
2.77 X
0.02 X
N/A
0.07 X
N/A
27.72 X
N/A
28.52 X
Gross Profit
3.04 M
564.14 M
N/A
N/A
(49.34 M)
11.44 B
N/A
5.98 B
Day Typical Price
0.84
1.67
31.81
0.24
0.07
16.69
9.91
31.62
Accumulation Distribution
N/A
N/A
0.006
N/A
N/A
0.0173
N/A
N/A
Market Facilitation Index
N/A
N/A
0.19
N/A
N/A
0.29
N/A
N/A
Daily Balance Of Power
9.2 T
(9,223,372,036,855)
(0.79)
9.2 T
0.0
1.551724
(9,223,372,036,855)
(9,223,372,036,855)
Period Momentum Indicator
0.01
(0.02)
(0.15)
0.01
N/A
0.45
(0.14)
(0.20)
Rate Of Daily Change
1.01
0.99
1.0
1.04
1.0
1.03
0.99
0.99
Day Median Price
0.84
1.67
31.82
0.24
0.07
16.65
9.91
31.62
Price Action Indicator
0.005
(0.01)
(0.09)
0.005
N/A
0.37
(0.07)
(0.10)
Coefficient Of Variation
8477.98
796.5
619.68
832.51
N/A
412.78
(1,013)
635.2
Mean Deviation
5.6
1.95
1.48
3.93
N/A
2.53
1.06
1.54
Jensen Alpha
0.0036
0.2863
0.3266
0.7355
N/A
0.7867
N/A
0.258
Total Risk Alpha
(1.03)
(0.05)
0.0314
(0.12)
N/A
0.3583
(0.33)
0.0233
Sortino Ratio
(0)
0.1023
0.119
0.0806
N/A
0.3663
N/A
0.1219
Downside Variance
51.16
4.18
2.89
49.38
N/A
4.33
N/A
2.46
Standard Deviation
7.98
2.56
1.95
5.65
N/A
3.61
1.33
1.92
Kurtosis
4.15
3.06
0.3
1.45
N/A
6.7
(0.43)
0.3763
Potential Upside
10.61
3.85
3.82
11.76
N/A
7.25
2.22
4.01
Treynor Ratio
0.1064
1.29
(1.39)
(1.01)
N/A
1.14
N/A
0.8562
Maximum Drawdown
42.86
14.33
9.44
32.65
N/A
20.02
6.12
10.25
Variance
63.75
6.53
3.79
31.87
N/A
13.01
1.77
3.7
Market Risk Adjusted Performance
0.1164
1.3
(1.38)
(1.00)
N/A
1.15
N/A
0.8662
Risk Adjusted Performance
0.0177
0.0984
0.1235
0.096
N/A
0.184
(0.07)
0.1206
Skewness
1.25
1.2
0.2359
0.4452
N/A
2.04
0.1743
0.3927
Semi Deviation
6.35
1.83
1.52
3.97
N/A
1.59
N/A
1.37
Information Ratio
(0)
0.0818
0.104
0.1003
N/A
0.2113
(0.18)
0.0993
Value At Risk
(12.50)
(3.09)
(2.44)
(8.00)
N/A
(3.07)
(2.19)
(2.71)
Expected Short fall
(6.94)
(2.33)
(1.70)
(7.17)
N/A
(3.14)
N/A
(1.87)
Downside Deviation
7.15
2.04
1.7
7.03
N/A
2.08
N/A
1.57
Semi Variance
40.29
3.34
2.3
15.77
N/A
2.52
N/A
1.87

Seres Therapeutics Competition Performance Charts

Five steps to successful analysis of Seres Therapeutics Competition

Seres Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Seres Therapeutics in relation to its competition. Seres Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Seres Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Seres Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Seres Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Seres Therapeutics position

In addition to having Seres Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Insurance Providers Thematic Idea Now

Insurance Providers
Insurance Providers Theme
Companies providing all types of insurance and insurance services. The Insurance Providers theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Insurance Providers Theme or any other thematic opportunities.
View All  Next Launch

Additional Information and Resources on Investing in Seres Stock

When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:
How To Invest In Seres
Details
Is Seres Stock a good investment?
Details
What is Seres Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Seres Therapeutics Correlation with its peers.
For more detail on how to invest in Seres Stock please use our How to Invest in Seres Therapeutics guide.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Altman
Z Score
Details
Intrinsic
Valuation
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY